(617) 481-4020
rapcancer@prostatehealthed.org
Facebook
Facebook
Contact
Home
Patient Summaries
Clinical Trials Basics
Learning Sessions
Patient Experiences
Newsletters
Blog
About PHEN Trials
About PHEN Trials
Sponsors
Contact
Select Page
Company News
How PHEN’s Clinical Trials Navigation Hotline Can Help You
April 2nd, 2024 | Company News
How can clinical researchers and pharmaceutical companies increase the diversity of their clinical trial subjects?
December 21st, 2023 | Company News
PHEN Hosts Successful Clinical Trials Learning Session with MSKCC
December 11th, 2023 | Company News
PHEN to Raise Prostate Cancer Awareness at the Cotton Bowl in Dallas, TX During the Annual State Fair Classic on September 30th
December 11th, 2023 | Company News
Search for:
Cancer Recurrence
Clinical Trial News
Clinical Trials
Cancer Recurrence
High Risk Prostate Cancer
Intermediate Risk Prostate Cancer
Low Risk Prostate Cancer
Metastatic Castration Resistant Prostate Cancer (MCRPC)
Metastatic Castration Sensitive Prostate Cancer (MCSPC)
Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)
Company News
High Risk Prostate Cancer
Intermediate Risk Prostate Cancer
Low Risk Prostate Cancer
Metastatic Castration Resistant Prostate Cancer (MCRPC)
Metastatic Castration Sensitive Prostate Cancer (MCSPC)
Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)
Patient Summaries
Amgen Patient Summaries
Janssen Patient Summaries
MacroGenics Patient Summaries
Merck Patient Summaries
Pfizer Patient Summaries
Webinars & Patient Experiences
All Patient Summaries
MEVPRO-2 Patient Summary – Metastatic Castration Resistant
MEVPRO-1 Patient Summary – Metastatic Castration Resistant
Libertas Patient Summary – Metastatic Castration Sensitive
Lorikeet Patient Summary – Metastatic Castration Resistant
AMG 509 Patient Summary – Metastatic Castration Resistant
Pin It on Pinterest